Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529005 | 1.00 | DNM1 (0.33) | DNM1 | |
| SCHEMBL711427 | 0.98 | DNM1 (0.30) | DNM1 | |
| SCHEMBL711432 | 0.91 | — | — | |
| SCHEMBL16615781 | 0.85 | DNM1 (0.36) | DNM1 | |
| SCHEMBL16615645 | 0.85 | DNM1 (0.36) | DNM1 | |
| SCHEMBL2533953 | 0.83 | EPHX2 (0.36) | DNM1 | |
| SCHEMBL2529833 | 0.83 | EPHX2 (0.36) | DNM1 | |
| SCHEMBL12978500 | 0.81 | DNM1 (0.50) | DNM1 | |
| SCHEMBL19822054 | 0.81 | DNM1 (0.50) | DNM1 | |
| SCHEMBL7777213 | 0.81 | DNM1 (0.50) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-RE39088-E1 | Amide compounds and use of the same | JAPAN TOBACCO, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| WO-2005082459-A2 | METHOD OF DECREASING BLOOD CELLS | JAPAN TOBACCO INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | JAPAN TOBACCO INC. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6639070-B1 | 4-substituted 1,3,4-oxadiazines; herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| EP-1187819-B1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| WO-2001000602-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-6150303-A | Substituted 3-phenylisoxazolines | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
| WO-2000023413-A1 | METHOD FOR DRYING PHENOXYMETHYLBENZOIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000001700-A1 | METHOD FOR PRODUCING ANELLATED TRIAZOLES AND NEW ANELLATED TRIAZOLES AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-13 | — | — | WO | disclosed |
| EP-0891336-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-20 | — | — | EP | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | DNM1 1396/4885 |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | TNF, IL1B, TNNI3 | DNM1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.